Cargando…
Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells
Dedifferentiated papillary thyroid cancer (DePTC) is characterized by aggressive growth, recurrence, distant metastasis, and resistance to radioactive iodine (RAI) therapy. DePTC is also accompanied by poor prognosis and high early-mortality. Nevertheless, most DePTC cells show intact p53 downstream...
Autores principales: | Chen, Haibo, Luo, Dingyuan, Zhang, Lin, Lin, Xiaofeng, Luo, Qiuyun, Yi, Hanjie, Wang, Jing, Yan, Xianglei, Li, Baoxia, Chen, Yuelei, Liu, Xingguang, Zhang, Hong, Liu, Sheng, Qiu, Miaozhen, Yang, Dajun, Jiang, Ningyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522123/ https://www.ncbi.nlm.nih.gov/pubmed/28498808 http://dx.doi.org/10.18632/oncotarget.17398 |
Ejemplares similares
-
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
por: Yi, Hanjie, et al.
Publicado: (2018) -
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
por: Luo, Qiuyun, et al.
Publicado: (2020) -
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
por: Traweek, Raymond S., et al.
Publicado: (2022) -
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019) -
MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
por: Fang, Douglas D., et al.
Publicado: (2021)